The Effect of Antineoplastic Drugs in a Male Spontaneous Mammary Tumor Model

被引:3
作者
Shishido, Stephanie N. [1 ]
Faulkner, Emma B. [1 ]
Beck, Amanda [1 ]
Nguyen, Thu A. [1 ]
机构
[1] Kansas State Univ, Coll Vet Med, Dept Diagnost Med & Pathobiol, Manhattan, KS 66506 USA
来源
PLOS ONE | 2013年 / 8卷 / 06期
关键词
MALE BREAST-CANCER; ESTROGEN-RECEPTOR-BETA; ANTI-APOPTOSIS GENE; CYCLIN D1; EXPRESSION; SURVIVIN; CELLS; CARCINOMA; DISEASE; BCL-2;
D O I
10.1371/journal.pone.0064866
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Male breast cancer is a rare disease. The limited number of clinical cases has led to the primary treatments for men being derived from female breast cancer studies. Here the transgenic strain FVB/N-Tg(MMTV-PyVT)634Mul/J ( also known as PyVT) was used as a model system for measuring tumor burden and drug sensitivity of the antineoplastic drugs tamoxifen, cisplatin, and paclitaxel on tumorigenesis at an early stage of mammary carcinoma development in a male mouse model. Cisplatin treatment significantly reduced tumor volume, while paclitaxel and tamoxifen did not attenuate tumor growth. Cisplatin treatment was shown to induce apoptosis, grossly observed by reduced tumor formation, through reduced Bcl-2 and survivin protein expression levels with an increase in caspase 3 expression compared to control tumors. Tamoxifen treatment significantly altered the hormone receptor expression levels of the tumor, while additionally upregulating Bcl-2 and Cyclin D1. This suggests an importance in hormonal signaling in male breast cancer pathogenesis. The results of this study provide valuable information toward the better understanding of male breast cancer and may help guide treatment decisions.
引用
收藏
页数:9
相关论文
共 60 条
  • [1] Adida C, 1998, AM J PATHOL, V152, P43
  • [2] Validating survivin as a cancer therapeutic target
    Altieri, DC
    [J]. NATURE REVIEWS CANCER, 2003, 3 (01) : 46 - 54
  • [3] A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
    Ambrosini, G
    Adida, C
    Altieri, DC
    [J]. NATURE MEDICINE, 1997, 3 (08) : 917 - 921
  • [4] Is male breast cancer similar or different than female breast cancer?
    Anderson, WF
    Althuis, MD
    Brinton, LA
    Devesa, SS
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2004, 83 (01) : 77 - 86
  • [5] Mammographic appearances of male breast disease
    Appelbaum, AH
    Evans, GFF
    Levy, KR
    Amirkhan, RH
    Schumpert, TD
    [J]. RADIOGRAPHICS, 1999, 19 (03) : 559 - 568
  • [6] Status of HER-2 in male and female breast carcinoma
    Bloom, KJ
    Govil, H
    Gattuso, P
    Reddy, V
    Francescatti, D
    [J]. AMERICAN JOURNAL OF SURGERY, 2001, 182 (04) : 389 - 392
  • [7] Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index
    Callagy, GM
    Pharoah, PD
    Pinder, SE
    Hsu, FD
    Nielsen, TO
    Ragaz, J
    Ellis, IO
    Huntsman, D
    Caldas, C
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (08) : 2468 - 2475
  • [8] Influence of cellular ERα/ERβ ratio on the ERα-agonist induced proliferation of human T47D breast cancer cells
    Covaleda, Ana M. Sotoca
    Van den Berg, Hans
    Vervoort, Jacques
    Van der Saag, Paul
    Strom, Anders
    Gustafsson, Jan-Ake
    Rietjens, Ivonne
    Murk, Albertinka J.
    [J]. TOXICOLOGICAL SCIENCES, 2008, 105 (02) : 303 - 311
  • [9] Mitochondrial survivin inhibits apoptosis and promotes tumorigenesis
    Dohi, T
    Beltrami, E
    Wall, NR
    Plescia, J
    Altieri, DC
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (08) : 1117 - 1127